Alto Neuroscience Stock Performance
| ANRO Stock | 15.08 1.45 8.77% |
Alto Neuroscience holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 5.39, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Alto Neuroscience will likely underperform. Use Alto Neuroscience value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Alto Neuroscience.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Alto Neuroscience are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Alto Neuroscience displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (8.77) | Five Day Return (15.99) | Year To Date Return (9.10) | Ten Year Return (27.15) | All Time Return (27.15) |
1 | Why institutional investors increase stakes in Alto Neuroscience Inc. stock - 2025 Volatility Report Smart Allocation Stock Tips - newser.com | 10/28/2025 |
2 | NYSE Content Advisory Pre-Market Update Government Shutdown Nears End After 42 Days | 11/11/2025 |
3 | Is Alto Neuroscience, Inc. Outperforming Other Medical Stocks This Year | 11/14/2025 |
4 | Wall Street Zen Upgrades Alto Neuroscience to Hold | 11/17/2025 |
5 | Alto Neuroscience Hits New 12-Month High Time to Buy | 11/20/2025 |
6 | Analysts Set Alto Neuroscience, Inc. Target Price at 23.83 | 12/01/2025 |
7 | Will Alto Neuroscience Inc. stock announce special dividend - Quarterly Earnings Summary Community Consensus Stock Picks - Newser | 12/04/2025 |
8 | Alto Neuroscience Shares Gap Down - Whats Next - MarketBeat | 12/16/2025 |
9 | Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating - Investing.com India | 01/05/2026 |
| Begin Period Cash Flow | 82.5 M | |
| Total Cashflows From Investing Activities | -2.1 M |
Alto Neuroscience Relative Risk vs. Return Landscape
If you would invest 602.00 in Alto Neuroscience on October 9, 2025 and sell it today you would earn a total of 906.00 from holding Alto Neuroscience or generate 150.5% return on investment over 90 days. Alto Neuroscience is currently generating 2.0665% in daily expected returns and assumes 12.0932% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Alto, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alto Neuroscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alto Neuroscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alto Neuroscience, and traders can use it to determine the average amount a Alto Neuroscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1709
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ANRO | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Alto Neuroscience is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alto Neuroscience by adding it to a well-diversified portfolio.
Alto Neuroscience Fundamentals Growth
Alto Stock prices reflect investors' perceptions of the future prospects and financial health of Alto Neuroscience, and Alto Neuroscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alto Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 405.1 M | ||||
| Shares Outstanding | 31.07 M | ||||
| Price To Book | 4.62 X | ||||
| EBITDA | (68.61 M) | ||||
| Net Income | (61.43 M) | ||||
| Total Debt | 16.94 M | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (47.42 M) | ||||
| Earnings Per Share | (2.30) X | ||||
| Market Capitalization | 513.53 M | ||||
| Total Asset | 177.54 M | ||||
| Retained Earnings | (138.4 M) | ||||
| Working Capital | 159.33 M | ||||
About Alto Neuroscience Performance
By examining Alto Neuroscience's fundamental ratios, stakeholders can obtain critical insights into Alto Neuroscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Alto Neuroscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.47) | (0.44) |
Things to note about Alto Neuroscience performance evaluation
Checking the ongoing alerts about Alto Neuroscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alto Neuroscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alto Neuroscience is way too risky over 90 days horizon | |
| Alto Neuroscience appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (61.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alto Neuroscience generates negative cash flow from operations | |
| About 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Institutional investors are Lyell Immunopharma, Inc.s biggest bettors and were rewarded after last weeks US72m market cap gain |
- Analyzing Alto Neuroscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alto Neuroscience's stock is overvalued or undervalued compared to its peers.
- Examining Alto Neuroscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alto Neuroscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alto Neuroscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alto Neuroscience's stock. These opinions can provide insight into Alto Neuroscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alto Neuroscience is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience's market value can be influenced by many factors that don't directly affect Alto Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.